Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to sell a 50% controlling stake of its consumer health business Opella for 10 ...

The four anti-CD20 drugs used in the U.S. to treat relapsing MS -- ocrelizumab, ofatumumab, and ublituximab (Briumvi; ...

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader. Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Adding nbUVB phototherapy to oral ritlecitinib improves facial and total body repigmentation in patients with nonsegmental ...

The pan-African i3 programme has selected 7 growth-stage startups—Chefaa, Dawa Mkononi, Meditect, mPharma, myDawa, RxAll, ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products and could be used to respond to an emerging pandemic ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Indian Oil Corporation consolidated net profit rises 57.78% in the March 2025 quarter Vedanta consolidated net profit rises 154.42% in the March 2025 quarter Sanofi Consumer Healthcare India Ltdhas ...